FDA warned Hangzhou Huiji Biotechnology over CGMP failures in OTC hand sanitizers, including missing glycerin and ethanol safety tests.
What happened
FDA reviewed records the company submitted after FDA's March 4, 2024 request for records under section 704(a)(4) of the FD&C Act; there was no inspection. FDA found the company did not test each incoming glycerin lot for diethylene glycol/ethylene glycol or incoming ethanol for methanol, did not adequately test finished hand sanitizer for ethanol identity and strength before release, and lacked adequate quality-unit oversight. FDA placed the firm on Import Alert 66-40 on November 15, 2024, and cited current good manufacturing practice (CGMP) violations that make the drugs adulterated.
What FDA found
The company did not test every incoming shipment of drug ingredients to confirm identity; for glycerin it skipped USP limit tests for DEG and EG, and for ethanol it skipped methanol testing.
21 CFR 211.84(d)(1)The company did not adequately test each finished batch for identity and strength of ethanol before release and did not show its test method was suitable.
21 CFR 211.165(a) and 211.165(e)The quality unit did not ensure proper batch records, stability data to support expiry, or adequate design and monitoring of the water system.
21 CFR 211.22(a)
What FDA wants
FDA tells the company to correct the violations promptly and respond in writing within 15 working days with corrective actions and prevention steps; if it cannot finish, it must explain the delay and give a completion schedule. FDA also recommends a qualified CGMP consultant and a six-system audit.
Who should pay attention
- US brands, distributors, and retailers selling OTC hand sanitizers made by this firm
- importers and buyers of Chinese OTC drugs or cosmetics
- contract manufacturers and suppliers using glycerin or ethanol
This is a summary. Read the original letter on fda.gov.